Investor Relations

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and progressing its pipeline of novel therapeutic candidates in cancer, cachexia (wasting syndrome) and Pulmonary Arterial Hypertension (PAH).

NASDAQ | AVEO (Common Stock)
$1.25 + 0.52
Stock chart for: AVEO.O.  Currently trading at $1.25 with a 52 week high of $1.09 and a 52 week low of $0.50.
06/23/17 4:00 p.m. ET
Data Provided by Thomson Reuters

Press Releases

AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell CarcinomaRead More
AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma Reaches Enrollment TargetRead More
AVEO Oncology Announces Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in RCC Advances to Phase 2Read More